FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1104-1111 March 20, 2003 Number 12 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Freedman, J. E. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition in patients with acute coronary syndromes.

Methods Serum levels of soluble CD40 ligand were measured in 1088 patients with acute coronary syndromes who had previously been enrolled in a randomized trial comparing abciximab with placebo before coronary angioplasty and in 626 patients with acute chest pain.

Results The levels of soluble CD40 ligand were elevated (above 5.0 µg per liter) in 221 patients with acute coronary syndromes (40.6 percent). Among patients receiving placebo, elevated soluble CD40 ligand levels indicated a significantly increased risk of death or nonfatal myocardial infarction during six months of follow-up (adjusted hazard ratio as compared with patients with low levels of the ligand [5.0 µg per liter], 2.71; 95 percent confidence interval, 1.51 to 5.35; P=0.001). The prognostic value of this marker was validated in the patients with chest pain, among whom elevated soluble CD40 ligand levels identified those with acute coronary syndromes who were at high risk for death or nonfatal myocardial infarction (adjusted hazard ratio as compared with those with low levels of the ligand, 6.65; 95 percent confidence interval, 3.18 to 13.89; P<0.001). The increased risk in patients with elevated soluble CD40 ligand levels was significantly reduced by treatment with abciximab (adjusted hazard ratio as compared with those receiving placebo, 0.37; 95 percent confidence interval, 0.20 to 0.68; P=0.001), whereas there was no significant treatment effect of abciximab in patients with low levels of soluble CD40 ligand.

Conclusions In patients with unstable coronary artery disease, elevation of soluble CD40 ligand levels indicated an increased risk of cardiovascular events. Elevation of soluble CD40 ligand identifies a subgroup of patients at high risk who are likely to benefit from antiplatelet treatment with abciximab.

Source Information

From the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study (C.H., S.D., C.W.H., M.J.B., E.B., A.M.Z., M.L.S.); Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany (C.H., S.D., A.M.Z.); the Kerckhoff Heart Center, Bad Nauheim, Germany (C.W.H.); and the Thoraxcentre, Erasmus University, Rotterdam, the Netherlands (M.J.B., E.B., M.L.S.).

Address reprint requests to Dr. Heeschen at the Department of Molecular Cardiology, Internal Medicine IV, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany, or at c.heeschen{at}em.uni-frankfurt.de.

Full Text of this Article

Related Letters:

Soluble CD40 Ligand in Acute Coronary Syndromes
Kritharides L., Lau G. T., Freedman B., Conde I. D., Kleiman N. S., Heeschen C., Hamm C. W., Zeiher A. M.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:2575-2577, Jun 19, 2003. Correspondence

This article has been cited by other articles:

• Menchen, L, Marin-Jimenez, I, Arias-Salgado, E G, Fontela, T, Hernandez-Sampelayo, P, Rodriguez, M C G., Butta, N V (2009). Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 58: 920-928 [Abstract] [Full Text]  
• Reichlin, T., Hochholzer, W., Stelzig, C., Laule, K., Freidank, H., Morgenthaler, N. G., Bergmann, A., Potocki, M., Noveanu, M., Breidthardt, T., Christ, A., Boldanova, T., Merki, R., Schaub, N., Bingisser, R., Christ, M., Mueller, C. (2009). Incremental value of copeptin for rapid rule out of acute myocardial infarction.. J Am Coll Cardiol 54: 60-68 [Abstract] [Full Text]  
• Hanusch-Enserer, U., Zorn, G., Wojta, J., Kopp, C. W., Prager, R., Koenig, W., Schillinger, M., Roden, M., Huber, K. (2009). Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J 30: 1516-1524 [Abstract] [Full Text]  
• URQUIZU-PADILLA, M., BALADA, E., CORTES, F., PEREZ, E. H., VILARDELL-TARRES, M., ORDI-ROS, J. (2009). Serum Levels of Soluble CD40 Ligand at Flare and at Remission in Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology 36: 953-960 [Abstract] [Full Text]  
• Lindahl, B. (2009). Multimarker Approach for Diagnosis of Acute Myocardial Infarction: Better Answers Need Better Questions. Clin. Chem. 55: 9-11 [Full Text]  
• Apple, F. S., Smith, S. W., Pearce, L. A., Murakami, M. M. (2009). Assessment of the Multiple-Biomarker Approach for Diagnosis of Myocardial Infarction in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome. Clin. Chem. 55: 93-100 [Abstract] [Full Text]  
• Plaikner, M., Peer, A., Falkensammer, G., Schmidauer, C., Pechlaner, C., Griesmacher, A., Pachinger, O., Mair, J. (2009). Lack of Association of Soluble CD40 Ligand with the Presence of Acute Myocardial Infarction or Ischemic Stroke in the Emergency Department. Clin. Chem. 55: 175-178 [Abstract] [Full Text]  
• Aukrust, P., Halvorsen, B., Yndestad, A., Ueland, T., Oie, E., Otterdal, K., Gullestad, L., Damas, J. K. (2008). Chemokines and Cardiovascular Risk. Arterioscler. Thromb. Vasc. Bio. 28: 1909-1919 [Abstract] [Full Text]  
• Chen, C., Chai, H., Wang, X., Jiang, J., Jamaluddin, M. S., Liao, D., Zhang, Y., Wang, H., Bharadwaj, U., Zhang, S., Li, M., Lin, P., Yao, Q. (2008). Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 112: 3205-3216 [Abstract] [Full Text]  
• Choudhury, A., Chung, I., Panja, N., Patel, J., Lip, G. Y. H. (2008). Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation: Relationship to Soluble P-Selectin, Stroke Risk Factors, and Risk Factor Intervention. Chest 134: 574-581 [Abstract] [Full Text]  
• Dai, D.-F., Thajeb, P., Tu, C.-F., Chiang, F.-T., Chen, C.-H., Yang, R.-B., Chen, J.-J. (2008). Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke.. J Am Coll Cardiol 51: 2173-2180 [Abstract] [Full Text]  
• Morrow, D. A., Sabatine, M. S., Brennan, M.-L., de Lemos, J. A., Murphy, S. A., Ruff, C. T., Rifai, N., Cannon, C. P., Hazen, S. L. (2008). Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29: 1096-1102 [Abstract] [Full Text]  
• Weber, M., Hamm, C. (2008). Novel biomarkers--the long march from bench to bedside. Eur Heart J 29: 1079-1081 [Full Text]  
• Li, G., Sanders, J. M., Bevard, M. H., Sun, Z., Chumley, J. W., Galkina, E. V., Ley, K., Sarembock, I. J. (2008). CD40 Ligand Promotes Mac-1 Expression, Leukocyte Recruitment, and Neointima Formation after Vascular Injury. Am. J. Pathol. 172: 1141-1152 [Abstract] [Full Text]  
• Nolan, A., Weiden, M., Kelly, A., Hoshino, Y., Hoshino, S., Mehta, N., Gold, J. A. (2008). CD40 and CD80/86 Act Synergistically to Regulate Inflammation and Mortality in Polymicrobial Sepsis. Am. J. Respir. Crit. Care Med. 177: 301-308 [Abstract] [Full Text]  
• Schernthaner, G., Morton, J. M. (2008). Bariatric Surgery in Patients With Morbid Obesity and Type 2 Diabetes. Diabetes Care 31: S297-S302 [Full Text]  
• Packard, R. R. S., Libby, P. (2008). Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. Clin. Chem. 54: 24-38 [Abstract] [Full Text]  
• Choudhury, A., Freestone, B., Patel, J., Lip, G. Y. H. (2007). Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and Tissue Factor in Atrial Fibrillation: A Link Among Platelet Activation, Angiogenesis, and Thrombosis?. Chest 132: 1913-1919 [Abstract] [Full Text]  
• Ferro, D., Loffredo, L., Polimeni, L., Fimognari, F., Villari, P., Pignatelli, P., Fuster, V., Violi, F. (2007). Soluble CD40 Ligand Predicts Ischemic Stroke and Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. Arterioscler. Thromb. Vasc. Bio. 27: 2763-2768 [Abstract] [Full Text]  
• Spagnoli, L. G., Bonanno, E., Sangiorgi, G., Mauriello, A. (2007). Role of Inflammation in Atherosclerosis. JNM 48: 1800-1815 [Abstract] [Full Text]  
• Cholette, J. M., Rubenstein, J. S., Alfieris, G. M., McDermott, M. P., Harmon, W. G., Vermilion, R., Eaton, M. P., Gangemi, J. J., Lerner, N. B. (2007). Elevated Risk of Thrombosis in Neonates Undergoing Initial Palliative Cardiac Surgery. Ann. Thorac. Surg. 84: 1320-1325 [Abstract] [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Ivandic, B. T., Spanuth, E., Haase, D., Lestin, H.-G., Katus, H. A. (2007). Increased Plasma Concentrations of Soluble CD40 Ligand in Acute Coronary Syndrome Depend on in Vitro Platelet Activation. Clin. Chem. 53: 1231-1234 [Abstract] [Full Text]  
• Ray, K. K., Morrow, D. A., Sabatine, M. S., Shui, A., Rifai, N., Cannon, C. P., Braunwald, E. (2007). Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome. Circulation 115: 3071-3078 [Abstract] [Full Text]  
• Prontera, C., Martelli, N., Evangelista, V., D'Urbano, E., Manarini, S., Recchiuti, A., Dragani, A., Passeri, C., Davi, G., Romano, M. (2007). Homocysteine Modulates the CD40/CD40L System. J Am Coll Cardiol 49: 2182-2190 [Abstract] [Full Text]  
• Zirlik, A., Bavendiek, U., Libby, P., MacFarlane, L., Gerdes, N., Jagielska, J., Ernst, S., Aikawa, M., Nakano, H., Tsitsikov, E., Schonbeck, U. (2007). TRAF-1, -2, -3, -5, and -6 Are Induced in Atherosclerotic Plaques and Differentially Mediate Proinflammatory Functions of CD40L in Endothelial Cells. Arterioscler. Thromb. Vasc. Bio. 27: 1101-1107 [Abstract] [Full Text]  
• Apple, F. S., Pearce, L. A., Chung, A., Ler, R., Murakami, M. M. (2007). Multiple Biomarker Use for Detection of Adverse Events in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome. Clin. Chem. 53: 874-881 [Abstract] [Full Text]  
• Altwegg, L. A., Neidhart, M., Hersberger, M., Muller, S., Eberli, F. R., Corti, R., Roffi, M., Sutsch, G., Gay, S., von Eckardstein, A., Wischnewsky, M. B., Luscher, T. F., Maier, W. (2007). Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 0: ehm078v3-8 [Abstract] [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation 115: e356-e375 [Full Text]  
• Alacacioglu, I., Ozcan, M. A., Piskin, O., Yuksel, F., Alacacioglu, A., Demirkan, F., Ozsan, H. G., Polat, M., Ozgenc, Y., Undar, B. (2007). Increased Concentration of Soluble CD40 Ligand in Preeclampsia. CLIN APPL THROMB HEMOST 13: 201-205 [Abstract]  
• Hammwohner, M., Ittenson, A., Dierkes, J., Bukowska, A., Klein, H. U., Lendeckel, U., Goette, A. (2007). Platelet Expression of CD40/CD40 Ligand and Its Relation to Inflammatory Markers and Adhesion Molecules in Patients with Atrial Fibrillation. Exp. Biol. Med. 232: 581-589 [Abstract] [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H., NACB COMMITTEE MEMBERS, , Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G., Jesse, R. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W., Wu, A. H.B. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Clin. Chem. 53: 552-574 [Full Text]  
• Hocher, B., Liefeldt, L., Quaschning, T., Kalk, P., Ziebig, R., Godes, M., Relle, K., Asmus, G., Stasch, J.-P. (2007). Soluble CD154 Is a Unique Predictor of Nonfatal and Fatal Atherothrombotic Events in Patients Who Have End-Stage Renal Disease and Are on Hemodialysis. J. Am. Soc. Nephrol. 18: 1323-1330 [Abstract] [Full Text]  
• Zirlik, A., Maier, C., Gerdes, N., MacFarlane, L., Soosairajah, J., Bavendiek, U., Ahrens, I., Ernst, S., Bassler, N., Missiou, A., Patko, Z., Aikawa, M., Schonbeck, U., Bode, C., Libby, P., Peter, K. (2007). CD40 Ligand Mediates Inflammation Independently of CD40 by Interaction With Mac-1. Circulation 115: 1571-1580 [Abstract] [Full Text]  
• Minoguchi, K., Yokoe, T., Tazaki, T., Minoguchi, H., Oda, N., Tanaka, A., Yamamoto, M., Ohta, S., O'Donnell, C. P., Adachi, M. (2007). Silent Brain Infarction and Platelet Activation in Obstructive Sleep Apnea. Am. J. Respir. Crit. Care Med. 175: 612-617 [Abstract] [Full Text]  
• Sui, Z., Sniderhan, L. F., Schifitto, G., Phipps, R. P., Gelbard, H. A., Dewhurst, S., Maggirwar, S. B. (2007). Functional Synergy between CD40 Ligand and HIV-1 Tat Contributes to Inflammation: Implications in HIV Type 1 Dementia. J. Immunol. 178: 3226-3236 [Abstract] [Full Text]  
• Anwaruddin, S., Askari, A. T., Topol, E. J. (2007). Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine. J Am Coll Cardiol 49: 279-289 [Abstract] [Full Text]  
• von Hundelshausen, P., Weber, C. (2007). Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease. Circ. Res. 100: 27-40 [Abstract] [Full Text]  
• Koenig, W., Khuseyinova, N. (2007). Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arterioscler. Thromb. Vasc. Bio. 27: 15-26 [Abstract] [Full Text]  
• Bedard, E., Rodes-Cabau, J., Houde, C., Mackey, A., Rivest, D., Cloutier, S., Noel, M., Marrero, A., Cote, J.-M., Chetaille, P., Delisle, G., Leblanc, M.-H., Bertrand, O. F. (2007). Enhanced Thrombogenesis but Not Platelet Activation Is Associated With Transcatheter Closure of Patent Foramen Ovale in Patients With Cryptogenic Stroke. Stroke 38: 100-104 [Abstract] [Full Text]  
• Lupia, E., Bosco, O., Bergerone, S., Dondi, A. E., Goffi, A., Oliaro, E., Cordero, M., Del Sorbo, L., Trevi, G., Montrucchio, G. (2006). Thrombopoietin Contributes to Enhanced Platelet Activation in Patients With Unstable Angina. J Am Coll Cardiol 48: 2195-2203 [Abstract] [Full Text]  
• Schafer, A., Flierl, U., Kobsar, A., Eigenthaler, M., Ertl, G., Bauersachs, J. (2006). Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats. Arterioscler. Thromb. Vasc. Bio. 26: 2813-2818 [Abstract] [Full Text]  
• Blankenberg, S., McQueen, M. J., Smieja, M., Pogue, J., Balion, C., Lonn, E., Rupprecht, H. J., Bickel, C., Tiret, L., Cambien, F., Gerstein, H., Munzel, T., Yusuf, S., for the HOPE Study Investigators, (2006). Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 114: 201-208 [Abstract] [Full Text]  
• Lee, S. P., Ataga, K. I., Orringer, E. P., Phillips, D. R., Parise, L. V. (2006). Biologically Active CD40 Ligand Is Elevated in Sickle Cell Anemia: Potential Role for Platelet-Mediated Inflammation. Arterioscler. Thromb. Vasc. Bio. 26: 1626-1631 [Abstract] [Full Text]  
• Malarstig, A., Lindahl, B., Wallentin, L., Siegbahn, A. (2006). Soluble CD40L Levels Are Regulated by the -3459 A>G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome. Arterioscler. Thromb. Vasc. Bio. 26: 1667-1673 [Abstract] [Full Text]  
• Antoniades, C., Tousoulis, D., Vasiliadou, C., Stefanadi, E., Marinou, K., Stefanadis, C. (2006). Genetic Polymorphisms of Platelet Glycoprotein Ia and the Risk for Premature Myocardial Infarction: Effects on the Release of sCD40L During the Acute Phase of Premature Myocardial Infarction. J Am Coll Cardiol 47: 1959-1966 [Abstract] [Full Text]  
• Vasan, R. S. (2006). Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations. Circulation 113: 2335-2362 [Full Text]  
• Weber, M., Rabenau, B., Stanisch, M., Elsaesser, A., Mitrovic, V., Heeschen, C., Hamm, C. (2006). Influence of Sample Type and Storage Conditions on Soluble CD40 Ligand Assessment. Clin. Chem. 52: 888-891 [Abstract] [Full Text]  
• Tedgui, A., Mallat, Z. (2006). Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways. Physiol. Rev. 86: 515-581 [Abstract] [Full Text]  
• Armstrong, E. J., Morrow, D. A., Sabatine, M. S. (2006). Inflammatory Biomarkers in Acute Coronary Syndromes: Part IV: Matrix Metalloproteinases and Biomarkers of Platelet Activation. Circulation 113: e382-e385 [Full Text]  
• Kobayashi, K., Nishimura, Y., Shimada, T., Yoshimura, S., Funada, Y., Satouchi, M., Yokoyama, M. (2006). Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome. Chest 129: 632-637 [Abstract] [Full Text]  
• Danese, S., Sans, M., Scaldaferri, F., Sgambato, A., Rutella, S., Cittadini, A., Pique, J. M., Panes, J., Katz, J. A., Gasbarrini, A., Fiocchi, C. (2006). TNF-{alpha} Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease. J. Immunol. 176: 2617-2624 [Abstract] [Full Text]  
• Nylaende, M, Kroese, A, Stranden, E, Morken, B, Sandbaek, G, Lindahl, A., Arnesen, H, Seljeflot, I (2006). Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 11: 21-28 [Abstract]  
• Nakamura, M., Tanaka, Y., Satoh, T., Kawai, M., Hirakata, M., Kaburaki, J., Kawakami, Y., Ikeda, Y., Kuwana, M. (2006). Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology (Oxford) 45: 150-156 [Abstract] [Full Text]  
• Santilli, F., Davi, G., Consoli, A., Cipollone, F., Mezzetti, A., Falco, A., Taraborelli, T., Devangelio, E., Ciabattoni, G., Basili, S., Patrono, C. (2006). Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus. J Am Coll Cardiol 47: 391-397 [Abstract] [Full Text]  
• Lenderink, T., Heeschen, C., Fichtlscherer, S., Dimmeler, S., Hamm, C. W., Zeiher, A. M., Simoons, M. L., Boersma, E., for the CAPTURE Investigators, (2006). Elevated Placental Growth Factor Levels Are Associated With Adverse Outcomes at Four-Year Follow-Up in Patients With Acute Coronary Syndromes. J Am Coll Cardiol 47: 307-311 [Abstract] [Full Text]  
• Clarke, M. W, Ward, N. C, Wu, J. H., Hodgson, J. M, Puddey, I. B, Croft, K. D (2006). Supplementation with mixed tocopherols increases serum and blood cell {gamma}-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes. Am. J. Clin. Nutr. 83: 95-102 [Abstract] [Full Text]  
• Willoughby, S. R., Stewart, S., Holmes, A. S., Chirkov, Y. Y., Horowitz, J. D. (2005). Platelet Nitric Oxide Responsiveness: A Novel Prognostic Marker in Acute Coronary Syndromes. Arterioscler. Thromb. Vasc. Bio. 25: 2661-2666 [Abstract] [Full Text]  
• Ginsburg, G. S., Donahue, M. P., Newby, L. K. (2005). Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics. J Am Coll Cardiol 46: 1615-1627 [Abstract] [Full Text]  
• Chakrabarti, S., Varghese, S., Vitseva, O., Tanriverdi, K., Freedman, J. E. (2005). CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates. Arterioscler. Thromb. Vasc. Bio. 25: 2428-2434 [Abstract] [Full Text]  
• Mitchell, A. M., Brown, M. D., Menown, I. B.A., Kline, J. A. (2005). Novel Protein Markers of Acute Coronary Syndrome Complications in Low-Risk Outpatients: A Systematic Review of Potential Use in the Emergency Department. Clin. Chem. 51: 2005-2012 [Abstract] [Full Text]  
• Davis, B., Zou, M.-H. (2005). CD40 Ligand-Dependent Tyrosine Nitration of Prostacyclin Synthase In Vivo. Circulation 112: 2184-2192 [Abstract] [Full Text]  
• Heeschen, C. (2005). Biomarkers in acute coronary syndromes and their role in diabetic patients. Diabetes and Vascular Disease Research 2: 122-127 [Abstract]  
• de Lemos, J. A., Zirlik, A., Schonbeck, U., Varo, N., Murphy, S. A., Khera, A., McGuire, D. K., Stanek, G., Lo, H. S., Nuzzo, R., Morrow, D. A., Peshock, R., Libby, P. (2005). Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study. Arterioscler. Thromb. Vasc. Bio. 25: 2192-2196 [Abstract] [Full Text]  
• Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., Bohm, M., Nickenig, G. (2005). Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. NEJM 353: 999-1007 [Abstract] [Full Text]  
• Hayashida, K., Kume, N., Murase, T., Minami, M., Nakagawa, D., Inada, T., Tanaka, M., Ueda, A., Kominami, G., Kambara, H., Kimura, T., Kita, T. (2005). Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome: A Novel Marker for Early Diagnosis. Circulation 112: 812-818 [Abstract] [Full Text]  
• Newby, A. C. (2005). Studying mechanisms underlying shedding of endothelial membrane proteins could help patients at risk for myocardial infarction. Cardiovasc Res 67: 4-5 [Full Text]  
• Ueland, T., Aukrust, P., Yndestad, A., Otterdal, K., Froland, S. S., Dickstein, K., Kjekshus, J., Gullestad, L., Damas, J. K. (2005). Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 26: 1101-1107 [Abstract] [Full Text]  
• Halldorsdottir, A. M., Stoker, J., Porche-Sorbet, R., Eby, C. S. (2005). Soluble CD40 Ligand Measurement Inaccuracies Attributable to Specimen Type, Processing Time, and ELISA Method. Clin. Chem. 51: 1054-1057 [Full Text]  
• Bavendiek, U., Zirlik, A., LaClair, S., MacFarlane, L., Libby, P., Schonbeck, U. (2005). Atherogenesis in Mice Does Not Require CD40 Ligand From Bone Marrow-Derived Cells. Arterioscler. Thromb. Vasc. Bio. 25: 1244-1249 [Abstract] [Full Text]  
• Fateh-Moghadam, S., Li, Z., Ersel, S., Reuter, T., Htun, P., Plockinger, U., Bocksch, W., Dietz, R., Gawaz, M. (2005). Platelet Degranulation Is Associated With Progression of Intima-Media Thickness of the Common Carotid Artery in Patients With Diabetes Mellitus Type 2. Arterioscler. Thromb. Vasc. Bio. 25: 1299-1303 [Abstract] [Full Text]  
• Varo, N., Libby, P., Nuzzo, R., Italiano, J., Doria, A., Schonbeck, U. (2005). Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diabetes and Vascular Disease Research 2: 81-87 [Abstract]  
• Apple, F. S., Wu, A. H.B., Mair, J., Ravkilde, J., Panteghini, M., Tate, J., Pagani, F., Christenson, R. H., Mockel, M., Danne, O., Jaffe, A. S., on behalf of the Committee on Standardization of M, (2005). Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin. Chem. 51: 810-824 [Abstract] [Full Text]  
• MacCallum, P. K. (2005). Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers. Proc Am Thorac Soc 2: 34-43 [Abstract] [Full Text]  
• Large, G A (2005). Contemporary management of acute coronary syndrome. Postgrad. Med. J. 81: 217-222 [Abstract] [Full Text]  
• Novo, S., Basili, S., Tantillo, R., Falco, A., Davi, V., Novo, G., Corrado, E., Davi, G. (2005). Soluble CD40L and Cardiovascular Risk in Asymptomatic Low-Grade Carotid Stenosis. Stroke 36: 673-675 [Abstract] [Full Text]  
• Tedgui, A. (2005). The role of inflammation in atherothrombosis: implications for clinical practice. Vasc Med 10: 45-53 [Abstract]  
• Schnabel, R., Rupprecht, H. J., Lackner, K. J., Lubos, E., Bickel, C., Meyer, J., Munzel, T., Cambien, F., Tiret, L., Blankenberg, S., for the AtheroGene Investigators, (2005). Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 26: 241-249 [Abstract] [Full Text]  
• Heeschen, C., Dimmeler, S., Hamm, C. W., Fichtlscherer, S., Simoons, M. L., Zeiher, A. M., CAPTURE Study Investigators, (2005). Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: Comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 45: 229-237 [Abstract] [Full Text]  
• Solanilla, A., Pasquet, J.-M., Viallard, J.-F., Contin, C., Grosset, C., Dechanet-Merville, J., Dupouy, M., Landry, M., Belloc, F., Nurden, P., Blanco, P., Moreau, J.-F., Pellegrin, J.-L., Nurden, A. T., Ripoche, J. (2005). Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 105: 215-218 [Abstract] [Full Text]  
• Moreno, P. R., Fuster, V. (2004). The year in atherothrombosis. J Am Coll Cardiol 44: 2099-2110 [Full Text]  
• Michelson, A. D. (2004). Platelet Function Testing in Cardiovascular Diseases. Circulation 110: e489-e493 [Full Text]  
• DeGraba, T. J. (2004). Immunogenetic Susceptibility of Atherosclerotic Stroke: Implications on Current and Future Treatment of Vascular Inflammation. Stroke 35: 2712-2719 [Abstract] [Full Text]  
• Schafer, A., Alp, N. J., Cai, S., Lygate, C. A., Neubauer, S., Eigenthaler, M., Bauersachs, J., Channon, K. M. (2004). Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo. Arterioscler. Thromb. Vasc. Bio. 24: 1720-1726 [Abstract] [Full Text]  
• Vishnevetsky, D., Kiyanista, V. A, Gandhi, P. J (2004). CD40 Ligand: A Novel Target in the Fight Against Cardiovascular Disease. The Annals of Pharmacotherapy 38: 1500-1508 [Abstract] [Full Text]  
• Akbiyik, F., Ray, D. M., Gettings, K. F., Blumberg, N., Francis, C. W., Phipps, R. P. (2004). Human bone marrow megakaryocytes and platelets express PPAR{gamma}, and PPAR{gamma} agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104: 1361-1368 [Abstract] [Full Text]  
• Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Sasiela, W. J., Szarek, M., Ganz, P., Libby, P., for the Myocardial Ischemia Reduction with Aggress, (2004). Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110: 386-391 [Abstract] [Full Text]